Influenza Vaccination Day 2014
Thursday, 13th March
Graduate House, Melbourne
ISG 2014 Annual Scientific Meeting a great success
The ISG's Annual Scientific Meeting took place on February 2nd & 3rd at the Park Royal Hotel at Melbourne Airport, and was by all reports a great success.
The ISG congratulates Sue Campbell-Lloyd on her Australia Day Honour
Sue Campbell-LLoyd is one of the founding members of the Influenza Specialist Group, and an active participant since 2006. She received her AM in recognition of her significant service to public health, through the promotion of immunisation programs.
Sue Campbell-Lloyd, AM
The winner of the inaugural ISG Annual Scientific Meeting travel scholarship has been announced.
The Influenza Specialist Group wishes to congratulate Anthea Katelaris on being awarded the ISG Annual Scientific Meeting travel scholarship for 2014 – the first time such a scholarship has been given.
Anthea is a final-year medical student with a passion for public health, influenza and vaccinology, and a demonstrable interest in influenza, having completed a year of research in the field, as well as an internship at the WHO Regional Office for Europe Vaccine-preventable Diseases Unit.
The ISG would also like to thank the other scholarship applicants for their submissions, all of which were of a very high standard.
Details of the 2015 scholarship will be made available during the course of 2014.
AIVC recommendations for the composition of influenza vaccine for Australia in 2014
The Australian Influenza Vaccine Committee (AIVC) met at TGA, Canberra, on 10 October 2013, to recommend influenza viruses to be used in the composition of the influenza vaccines for 2014.
On recommendation of the committee, the TGA has adopted the September WHO recommendations for the trivalent influenza vaccine components:
- A (H1N1): an A/California/7/2009 (H1N1) - like virus, 15 µg HA per dose
- A (H3N2): an A/Texas/50/2012 (H3N2) - like virus*, 15 µg HA per dose
- B: a B/Massachusetts/02/2012 - like virus, 15 µg HA per dose
Quadrivalent vaccines should contain viruses listed above, plus the additional B virus:
- B/Brisbane/60/2008-like virus, 15 µg HA per dose.
* A/Texas/50/2012 is an A(H3N2) virus that following adaptation to growth in eggs has maintained antigenic properties similar to the majority of recently circulating cell-propagated A(H3N2) viruses including A/Victoria/361/2011.
The ISG now has its own Facebook page!
Like the Influenza Specialist Group page on Facebook and support us in spreading the knowledge about influenza and influenza vaccination – just click the button: